Clinical Trial Update: Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention [Phase 2, Phase 3]

View source ↗

Summary

Trial update notes that Dehydroepiandrosterone (DHEA) was studied in systemic lupus erythematosus patients to prevent coronary artery disease, with Phase 2 and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Systemic Lupus Erythematosus

Drugs mentioned

• DHEA (Dehydroepiandrosterone) (Dehydroepiandrosterone)

Snippet

Sponsor: University of Michigan | Conditions: Systemic Lupus Erythematosus | Phase 2, Phase 3 | Status: COMPLETED